Stringent regulatory guidelines pertaining to cell and gene therapies has made it mandatory for developer companies to conduct extensive preclinical and clinical research to generate the necessary body of evidence, validating the safety, efficacy and benefits of their proprietary products. As a consequence, capital investments required in R&D have increased substantially. It is worth highlighting that even the well-established players in the industry are gradually opting to outsource certain aspects of their early-stage product development operations, such as preclinical research, clinical development, assessment of regulatory compliance and certain parts of the commercialization process, to contract service providers. In fact, as mentioned earlier in the report, there are a number of companies offering a wide range of R&D-related services, specifically for cell and gene therapies. Primarily driven by the need for technical and operational expertise, which are available with contract service providers, the cell and gene therapy bioassay services market is poised to witness substantial growth in the coming years.
To Request for Sample report –
During our research, we estimated the market under conservative, base and optimistic scenarios. As per the base case forecast scenario, the global cell and gene therapy bioassay services market is likely to be growing at a CAGR of 30.1%, during the given time period.
To Request for customize report –
Further, in terms of therapeutic area, the current market is dominated by oncological disorders, followed by infectious diseases. However, the clinical scale of operation is estimated to acquire a share of 65% in 2021, and this value is anticipated to grow at an annualized rate of 30% in the given time period.
In addition to this, North America is leading the current market estimated to capture ~60% shares of total market and anticipated to grow at an annualized rate of 49%, followed by Europe estimated to capture over 30% shares of the current market in 2021.
Besides this, it was observed that close to 60% of the total shares are captured by cell therapy domain and our estimates suggest that players offering services for cell therapies are likely to capture major share of the market. This can be attributed to the fact that a number of cell
therapies have already been commercialized and cell therapies capture a larger share of the overall biopharmaceutical industry
To request for report, click under – Cell and Gene Therapy Bioassay Services Market
You may also be interested in the following titles:
- Fc Fusion Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
- CRISPR Based Therapeutics Market: Industry Trends and Global Forecasts, 2020-2030
- Cell and Gene Therapy CROs Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
- TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
- TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
- CAR-T Cell Therapies Market: Industry Trends and Global Forecasts, 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at email@example.com
Contact Details Ben Johnson
+1 (415) 800 3415